We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
INmune Bio, the innate immunology company is proud to announce that it is now a publicly traded company (NASDAQ: INMB) and will be expanding its development programs. INMB is an immunology company that is focused on cancer with two programs in the clinic. INB03 targets myeloid derived suppressor cells (MDSC)., the cells known to cause resistance to immune checkpoint inhibitors (CPI). Combination of INB03 to inhibit MDSC should reverse resistance to CPI in an important group of patients who have failed CPI monotherapy. INKmune, a NK focused development program, has been given the green light by the MHRA to start clinical trials in women with relapsed/refractory ovarian cancer. INKmune is a biologic that prime the inert NK cells of the cancer patient to attack and kill their cancer. INMB is positioning INKmune to eliminate residual disease, the cancer that causes relapse and ultimately death in patients with cancer. INMB just completed an IPO to fund these programs into Phase II.